NOVEL BENZIMIDAZOLE DERIVATIVES

摘要

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:;;which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

主权项

1. A compound represented by Formula (I):or a pharmaceutically acceptable salt thereof, wherein:
D and Z are each independently absent or optionally substituted linear aliphatic group comprising zero to eight carbons; A and E are each independently absent or a cyclic group; wherein said each cyclic group is independently selected from the group consisting of aryl, heteroaryl, heterocyclic, C3-C8 cycloalkyl, and C3-C8 cycloalkenyl, each optionally substituted; T is absent or an optionally substituted aliphatic group; Wherein one to four of A, D, E, T and Z is absent; Ring B is a five-membered heteroaryl, wherein said heteroaryl is optionally substituted; R1 at each occurrence is independently selected from the group consisting of hydrogen, halogen, cyano, optionally substituted C1-C4 alkyl, —O—R11, —NRaRb, —C(O)R11, —CO2R11, and —C(O)NRaRb; R11 at each occurrence is independently hydrogen or optionally substituted C1-C8 alkyl; Ra and Rb at each occurrence are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, and optionally substituted C2-C8 alkenyl; or Ra and Rb can be taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic or optionally substituted heteroaryl group; u is independently 1, 2, or 3; Q and J are each independently selected from: R3 and R4 at each occurrence are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C3-C8 cycloalkyl; or alternatively, R3 and R4 can be taken together with the carbon atom to which they are attached to form optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclic; R5 at each occurrence is independently hydrogen, optionally substituted C1-C8 alkyl, or optionally substituted C3-C8 cycloalkyl; R6 is selected from the group consisting of —C(O)—R12, —C(O)—C(O)—R12, —S(O)2—R12, and —C(S)—R12; R12 at each occurrence is independently selected from the group consisting of —O—R11, —NRaRb, —R13, and —NRcRd; wherein R13 at each occurrence is independently selected from the group consisting of: hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, heterocyclic, aryl, and heteroaryl, each optionally substituted; and Rc and Rd at each occurrence are each independently selected from the group consisting of hydrogen, —R13, —C(O)—R13, —C(O)—OR13, —S(O)2—R13, —C(O)N(R13)2, and —S(O)2N(R13)2; m is 0, 1, or 2; n is 1, 2, 3, or 4; X at each occurrence is independently selected from O, S, S(O), SO2, and C(R7)2; provided that when m is 0, X is C(R7)2; and R7 at each occurrence is independently selected from the group consisting of: hydrogen, halogen, cyano, —NRaRb, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted —C1-C4 alkyl; or two vicinal R7 groups are taken together with the two adjacent atoms to which they are attached to form a fused, optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclic ring; or alternatively two geminal R7 groups are taken together with the carbon atom to which they are attached to form a Spiro, optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclic ring.